BIND Therapeutics (NASDAQ:BIND) is a developmental-stage drug company that went public on September 20th, 2013, at a price of $15/share. The stock currently trades at $13.90/share, with a market capitalization of $237M.
Here, I provide an overview of the company's long-term prospects, as well as a valuation of the shares based on a probabilistic discounted cash flow model.
Management and Insider Ownership
A number of important insiders are heavily invested in BIND, including its two founders, Omid Farokhzad (2.3% of company) and Robert Langer, an Institute Professor at MIT and founder of a number of other companies (5.3% of company). David H. Koch also owns 6% of the company, which was upped to 8.9% after the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|